In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GPOs Cry Foul Following Senate Hearings

Executive Summary

Facing intense scrutiny from both Senate hearings and a series of articles in the New York Times, GPO executives scramble to defend their practices even as they promise to pay more attention to the issues their critics raise.

You may also be interested in...

Our Top Ten Items from a Year Most Want to Forget

From the bear market, to the growing management credibility gap, to GPO whistleblowers, 2002 was a year most of us are glad to have behind us. But within the gloom, some glimmers of hope: most important among them is a sense of directionality at athe FDA following the appointment of a new commissioner.

The Realpolitik of the Device Industry

After years of criticizing medical technology advances as a cause of rising healthcare costs, many health policy experts and economists are coming around to the view that technology can reduce costs. But such a positive view of technology is worthless if hospitals won't pay a reasonable price for products. A recent New York Times article blasted hospital group purchasing for blocking access to new technology. But it was wrong--the real danger is that group purchasing is destroying hospitals' access to products that already exist.

Hospital, Heal Thyself

Some time in the next several months, the hospital group purchasing organization will undergo a level of public scrutiny that it has never experienced before. Two US senators are gearing up to hold hearings on the industry, specifically to explore the negative impact that group purchasing has had on competition among medical device and hospital supply companies. Ironically, one could argue that rather than pitting hospitals against suppliers, group purchasing could eventually prove about as bad for hospitals as it has been for some suppliers. By reducing the number of competitors in product categories, by creating the very oligopolies that small suppliers rail against, GPOs, and by extension the hospitals they serve--have boxed themselves into a corner.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts